



Dkt. 2259/58463/JPW/AJM/CY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Harold J. Wanebo and Shashikant Mehta
Serial No. : 09/287,884 Examiner: J.D. Goldberg
Filed : April 7, 1999 Group Art Unit: 1614
For : COMBINATIONS OF CERAMIDE AND CHEMOTHERAPEUTIC
AGENTS FOR INDUCING CELL DEATH AND USES THEREOF

1185 Avenue of the Americas
New York, NY 10036
June 18, 2004

VIA HAND

U.S. Patent and Trademark Office
220 20th Street S.
Customer Window, Mail Stop Petition
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

RECEIVED
JUN 18 2004
OFFICE OF PETITIONS

Mail Stop Petition

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following disclosures, which are listed on Form PTO-1449 (**EXHIBIT A**). Copies of the disclosures listed below as items 1-4 are attached hereto as **EXHIBITS 1-4**, respectively.

1. U.S. Patent No. 5,478,860 A, issued to Wheeler, et al., December 26, 1995 (**EXHIBIT 1**);
2. Myrick, D., et al., "Taxol and ceramide act synergistically in the growth inhibition of Jurkat, a

leukemic T-cell line", FASEB Journal, Vol. 11, no. 2, page A546 (Abstract, 1997) (**EXHIBIT 2**);

3. Myrick, D.C., et al., "Paclitaxel-induced apoptosis in Jurkat, a leukemic T-cell, is enhanced by ceramide", FASEB Journal, Vol. 13, no. 4, Part 1, page A191 (Abstract, March 12, 1999) (**EXHIBIT 3**); and
4. Myrick, Dorkina, et al., "Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide", Leukemia Research, Vol. 23, no. 6, pages 569-578 (June 1999) (**EXHIBIT 4**).


A Supplementary European Search Report was issued on February 19, 2004 in connection with related European Application No. EP 00 92 3188. A copy of the February 19, 2004 Supplementary European Search Report is attached hereto as **EXHIBIT 5**. The above-listed references 1-4 were cited in that Search Report.

If a telephone conference would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants: Harold J. Wanebo and Shashikant Mehta
Serial No.: 09/287,884
Filed: April 7, 1999
Page 3

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if a fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

A handwritten signature in dark ink, appearing to be 'John P. White', is written above a horizontal line. The signature is stylized with a large, sweeping loop.

John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

2259/58463

JPW/AJM/CY

Serial No.

09/287,884

Applicant(s)

Harold J. Wanebo and Shashikant Mehta

Filing Date

April 7, 1999

Group

1614

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5 4 7 8 8 6 0	12/26/95	Wheeler (Exhibit 1)			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Myrick, D., et al., "Taxol and ceramide act synergistically in the growth inhibition of Jurkat, a leukemic T-cell line", <u>FASEB Journal</u> , Vol. 11, no. 2, page A546 (Abstract, 1997) (Exhibit 2);
	Myrick, D.C., et al., "Paclitaxel-induced apoptosis in Jurkat, a leukemic T-cell, is enhanced by ceramide", <u>FASEB Journal</u> , Vol. 13, no. 4, Part 1, page A191 (Abstract, March 12, 1999) (Exhibit 3); and
	Myrick, Dorkina, et al., "Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide", <u>Leukemia Research</u> , Vol. 23, no. 6, pages 569-578 (June 1999) (Exhibit 4).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Wanebo and Mehta
Serial No.: 09/287,884
Filed: April 7, 1999
Exhibit A

